|
|
 Previous Article | Table of Contents | Next Article 
High Levels of Wilms' Tumor Gene (wt1) mRNA in Acute Myeloid Leukemias Are Associated With a Worse Long-Term Outcome
Lothar Bergmann,
Cornelius Miething,
Ulrich Maurer,
Jürgen Brieger,
Tunca Karakas,
Eckhart Weidmann, and
Dieter Hoelzer
From the Medical Clinic III, Hematology/Oncology, J.W. Goethe University, Frankfurt, Germany.
The tumor suppressor gene wt1 (Wilms' tumor gene) encodes for a zinc finger DNA-binding protein with predominantly transcription repressing properties. Because wt1 has been shown to be expressed in the vast majority of patients with acute myeloid leukemias (AML), we investigated the relevance of wt-1 mRNA expression regarding prognosis and possible prediction of relapse during follow-up. Totally bone marrow-derived blasts of 139 AML patients (129 newly diagnosed AML patients, 22 AML patients again in first relapse, and 10 AML patients analyzed primarily in first relapse) were studied for wt1 mRNA expression. Seventy-seven patients were analyzed for wt1 mRNA expression during follow-up. wt1-specific reverse transcription-polymerase chain reaction (RT-PCR) was performed and the amplification product was visually classified as not, weakly, moderately, or strongly amplified, as described previously. PCR products were quantitated by competitive PCR using a shortened homologous wt1 construct standard in representative cases. The expression of wt1 transcripts was correlated to age, French-American-British (FAB) subtype, phenotype, karyotype, and long-term survival. wt1 mRNA was detectable in 124 of 161 (77%) samples at diagnosis and in first relapse. wt1 expression was independent from age, antecedent myelodysplastic syndrome or FAB subtype, with the exception of a significant difference in M5 leukemias showing wt1 transcripts in only 40% (P = .0025). There was no correlation between the level of wt1 mRNA and response to treatment or the prognostic groups defined by the karyotype. Concerning long-term survival, patients with high levels of wt1 had a significantly worse overall survival (OS) than those with not detectable or low levels. The 3-year OS for all newly diagnosed AMLs was 13% and 38% (P = .038), respectively, and 12% and 43% (P = .014) for de novo AMLs. The difference was more distinct in patients less than 60 years of age. During follow-up, all patients achieving complete remission became wt1 negative. Reoccurrence of wt1 transcripts predicted relapse. The data indicate that high expression of wt1 mRNA is associated with a worse long-term prognosis.
Blood, Vol. 90 No. 3 (August 1), 1997:
pp. 1217-1225
© 1997 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J. W. King, S. Thomas, F. Corsi, L. Gao, R. Dina, R. Gillmore, K. Pigott, A. Kaisary, H. J. Stauss, and J. Waxman
IL15 Can Reverse the Unresponsiveness of Wilms' Tumor Antigen-Specific CTL in Patients with Prostate Cancer
Clin. Cancer Res.,
February 15, 2009;
15(4):
1145 - 1154.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Letavernier, P. Bruneval, S. Vandermeersch, J. Perez, C. Mandet, M.-F. Belair, J.-p. Haymann, C. Legendre, and L. Baud
Sirolimus interacts with pathways essential for podocyte integrity
Nephrol. Dial. Transplant.,
February 1, 2009;
24(2):
630 - 638.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Greiner, L. Bullinger, B.-a. Guinn, H. Dohner, and M. Schmitt
Leukemia-Associated Antigens Are Critical for the Proliferation of Acute Myeloid Leukemia Cells
Clin. Cancer Res.,
November 15, 2008;
14(22):
7161 - 7166.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Paschka, G. Marcucci, A. S. Ruppert, S. P. Whitman, K. Mrozek, K. Maharry, C. Langer, C. D. Baldus, W. Zhao, B. L. Powell, et al.
Wilms' Tumor 1 Gene Mutations Independently Predict Poor Outcome in Adults With Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
J. Clin. Oncol.,
October 1, 2008;
26(28):
4595 - 4602.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. P. Radich
Molecular Classification of Acute Myeloid Leukemia: Are We There Yet?
J. Clin. Oncol.,
October 1, 2008;
26(28):
4539 - 4541.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Makki, T. Heinzel, and C. Englert
TSA downregulates Wilms tumor gene 1 (Wt1) expression at multiple levels
Nucleic Acids Res.,
July 1, 2008;
36(12):
4067 - 4078.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Rezvani, A. S. M. Yong, S. Mielke, B. N. Savani, L. Musse, J. Superata, B. Jafarpour, C. Boss, and A. J. Barrett
Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies
Blood,
January 1, 2008;
111(1):
236 - 242.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Meshinchi and R. J. Arceci
Prognostic Factors and Risk-Based Therapy in Pediatric Acute Myeloid Leukemia
Oncologist,
March 1, 2007;
12(3):
341 - 355.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Greiner, M. Schmitt, L. Li, K. Giannopoulos, K. Bosch, A. Schmitt, K. Dohner, R. F. Schlenk, J. R. Pollack, H. Dohner, et al.
Expression of tumor-associated antigens in acute myeloid leukemia: implications for specific immunotherapeutic approaches
Blood,
December 15, 2006;
108(13):
4109 - 4117.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Heuser, G. Beutel, J. Krauter, K. Dohner, N. von Neuhoff, B. Schlegelberger, and A. Ganser
High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics
Blood,
December 1, 2006;
108(12):
3898 - 3905.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. A. Simpson, E. A. Burwell, K. A. Thompson, S. Shahnaz, A. R. Chen, and D. M. Loeb
The antiapoptotic gene A1/BFL1 is a WT1 target gene that mediates granulocytic differentiation and resistance to chemotherapy
Blood,
June 15, 2006;
107(12):
4695 - 4702.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Lapillonne, A. Renneville, A. Auvrignon, C. Flamant, A. Blaise, C. Perot, J.-L. Lai, P. Ballerini, F. Mazingue, S. Fasola, et al.
High WT1 Expression After Induction Therapy Predicts High Risk of Relapse and Death in Pediatric Acute Myeloid Leukemia
J. Clin. Oncol.,
April 1, 2006;
24(10):
1507 - 1515.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Gillmore, S.-A. Xue, A. Holler, J. Kaeda, D. Hadjiminas, V. Healy, R. Dina, S. C. Parry, I. Bellantuono, Y. Ghani, et al.
Detection of Wilms' Tumor Antigen-Specific CTL in Tumor-Draining Lymph Nodes of Patients with Early Breast Cancer
Clin. Cancer Res.,
January 1, 2006;
12(1):
34 - 42.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Greiner, L. Li, M. Ringhoffer, T. F. E. Barth, K. Giannopoulos, P. Guillaume, G. Ritter, M. Wiesneth, H. Dohner, and M. Schmitt
Identification and characterization of epitopes of the receptor for hyaluronic acid-mediated motility (RHAMM/CD168) recognized by CD8+ T cells of HLA-A2-positive patients with acute myeloid leukemia
Blood,
August 1, 2005;
106(3):
938 - 945.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Renshaw, R. M. Orr, M. I. Walton, R. te Poele, R. D. Williams, E. V. Wancewicz, B. P. Monia, P. Workman, and K. Pritchard-Jones
Disruption of WT1 gene expression and exon 5 splicing following cytotoxic drug treatment: Antisense down-regulation of exon 5 alters target gene expression and inhibits cell survival
Mol. Cancer Ther.,
November 1, 2004;
3(11):
1467 - 1484.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Oka, A. Tsuboi, T. Taguchi, T. Osaki, T. Kyo, H. Nakajima, O. A. Elisseeva, Y. Oji, M. Kawakami, K. Ikegame, et al.
Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression
PNAS,
September 21, 2004;
101(38):
13885 - 13890.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Alberta, G. M. Springett, H. Rayburn, T. A. Natoli, J. Loring, J. A. Kreidberg, and D. Housman
Role of the WT1 tumor suppressor in murine hematopoiesis
Blood,
April 1, 2003;
101(7):
2570 - 2574.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S.-i. Fujii, K. Shimizu, F. Koji, and F. Kawano
Malignant counterpart of myeloid dendritic cell (DC) belonging to acute myelogenous leukemia (AML) exhibits a dichotomous immunoregulatory potential
J. Leukoc. Biol.,
January 1, 2003;
73(1):
82 - 90.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. E. Heslop, F. K. Stevenson, and J. J. Molldrem
Immunotherapy of Hematologic Malignancy
Hematology,
January 1, 2003;
2003(1):
331 - 349.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Ghanem, T. H. Van der Kwast, J. C. Den Hollander, M. K. Sudaryo, M. H. A. Oomen, M. A. Noordzij, M. M. Van den Heuvel, S. M. Nassef, R. M. Nijman, and G. J. Van Steenbrugge
Expression and Prognostic Value of Wilms' Tumor 1 and Early Growth Response 1 Proteins in Nephroblastoma
Clin. Cancer Res.,
November 1, 2000;
6(11):
4265 - 4271.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Gaiger, V. Reese, M. L. Disis, and M. A. Cheever
Immunity to WT1 in the animal model and in patients with acute myeloid leukemia
Blood,
August 15, 2000;
96(4):
1480 - 1489.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Ohminami, M. Yasukawa, and S. Fujita
HLA class I-restricted lysis of leukemia cells by a CD8+ cytotoxic T-lymphocyte clone specific for WT1 peptide
Blood,
January 1, 2000;
95(1):
286 - 293.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. McCoy, S. B. McGee, and M. M. Cornwell
The Wilms' Tumor Suppressor, WT1, Inhibits 12-O-Tetradecanoylphorbol-13-acetate Activation of the Multidrug Resistance-1 Promoter
Cell Growth Differ.,
June 1, 1999;
10(6):
377 - 386.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
U. Maurer, F. Jehan, C. Englert, G. Hubinger, E. Weidmann, H. F. DeLuca, and L. Bergmann
The Wilms' Tumor Gene Product (WT1) Modulates the Response to 1,25-Dihydroxyvitamin D3 by Induction of the Vitamin D Receptor
J. Biol. Chem.,
February 2, 2001;
276(6):
3727 - 3732.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
